Market depth analysis for Tempus stock price forecast shows consistent bid support at $41 levels. This points to healthy investor demand and a cushion against near-term downside risks in volatile trading conditions. Revenue Miss : Despite a 36% year-over-year revenue increase, the figure fell short of our projection by 2.7%. Tempus AIâs oncology segment integrates genomic testing, liquid biopsies, and AI-driven diagnostics to personalize treatment decisions. Earnings surprise potential is another catalyst for the Tempus stock price forecast. Historical data shows the company beating estimates in four of the past five quarters, lifting investor confidence.